Periodic Reporting for period 1 - platinDx (A test for predicting the efficacy of common platinum drugs enabling personalized chemotherapy for bladder cancer patients.)
Reporting period: 2015-05-01 to 2015-10-31
AMD undertook the feasibility study from May 1 to October 31 2015 with the objective to assess the commercial potential of their PlatinDx test and to outline a strategy for commercialisation in the EU.
Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far
AMD contacted potential partners for developing a manufacturing supply chain, clinical validation and regulatory approval of the test. We defined the clinical, drug substance and drug product, and mass spectrometry validation requirments.
Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)
We identified all of the required stakeholders for a Phase II project, confirmed the business case for commercialization of the test. Upon implementation, the test will improve the overall efficacy of chemotherapy and reduce needless suffering from toxic side effects while saving costs for the health care system at large, both in the EU and globally.